

PHARMANUTRA S.P.A. LAUNCHES NEW PRODUCTS

CETILAR® ORO AND APPORTAL® VITAL

Two new food supplements, on sale in stores from today, will further expand the existing Cetilar® and ApportAL® lines.

Pisa, 15 September 2022 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialized in mineral-based nutritional supplements and medical devices for muscles and joints, is expanding its product portfolio with **the launch of its new products Cetilar® Oro and ApportAL® Vital**. Officially unveiled at the PharmaNutra 2022 National Convention, taking place from today until Sunday 18 September in Porto Cervo (Sassari), the new food supplements, which will be on sale in pharmacies from today, are an important extension of the Cetilar® and ApportAL® lines.

Cetilar® Oro is a food supplement containing Cetylated Fatty Acids (CFA), and the first oral formulation product in the Cetilar® line, which up to date has consisted solely of topical products for reducing musculoskeletal pain resulting from injuries, contractures, strains, bruises or sprains. In this sense, Cetilar® Oro is an absolute novelty for the market of products dedicated to the well-being of muscles and joints, since it is the only food supplement in orosoluble sachets consisting in a blend of Cetylated Fatty Acids (CFA), an exclusive patent of PharmaNutra.

New product **ApportAL® Vital** will be placed on the market by Junia Pharma S.r.l., a subsidiary company specialized in the development and distribution of medical devices and food supplements specifically for the paediatric sector. Like the well-known food supplement ApportAL®, the Vital version contains 19 nutrients, including vitamins, Sucrosomial® minerals, amino acids, royal jelly and coenzyme Q10, and is ideal for all those times at which the body requires rapid recovery, for example in the case of fatigue, weakness and tiredness, but also convalescence and poor appetite, without forgetting the positive effects on the immune defences.

"The launch of Cetilar® Oro is the result of years of work by our R&D and Regulatory teams, thanks to whom we obtained EU classification of the Cetylated Fatty Acids (CFA) as a Novel Food. We are now finally ready to place an absolutely innovative, safe and effective product on the market," declares Germano Tarantino, Chief Scientific Officer at PharmaNutra S.p.A. "ApportAL® Vital, on the other hand, is the direct result of the success obtained in recent years by ApportAL®, of which it retains the energising and restorative characteristics, through the use of Sucrosomial® Technology, and excellent palatability. The main advantage of this product is the new formulation enriched with Royal Jelly and Coenzyme Q10, and which is suitable for all ages."

"We are extremely proud to launch the first oral product containing Cetylated Fatty Acids (CFA), a unique patent that we have continuously improved over the years. Cetilar® Oro is an innovative food supplement based on the great experience and effectiveness of our Cetilar® products, but in a practical and immediate orosoluble formula. The same can be said of ApportAL® Vital, the first variant of a new range that will be placed on the market over the next few years. The purpose of this new product is to guarantee the same effectiveness as ApportAL®, which in just a few years has become one of PharmaNutra's bestsellers, to offer valid support also to a younger target, thanks to a specific formulation," **adds Andrea Lacorte, Chairman of the PharmaNutra Group.**

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Deputy Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique food supplements and innovative nutrition devices by carrying out the entire production process, from the proprietary starting materials through to the finished product. The effectiveness of its products is demonstrated by a wealth of scientific evidence, including 135 publications involving more than 7000 subjects. The Group distributes and places its products on the market in Italy and abroad. Within Italy, sales activities are carried out through a network of over 160 medical science liaisons serving the medical profession, as well as focusing on the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales activities are guaranteed abroad in more than 60 different countries through 42 partners chosen amongst the best pharmaceutical companies. PharmaNutra is a market leader in the manufacture of dietary supplements containing iron with its SiderAL® brand, where it boasts important patents covering its Sucrosomial® Technology. Over the years, the Group has developed a precise strategy regarding the management and production of intellectual property, based on integrated management of all the various components: proprietary starting materials, patents, brands and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com